Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches (Q34997082)

5 August 2017

1 reference

title

Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches (English)

1 reference

5 August 2017

1 reference

1 reference

van Moorselaar RJ

1 reference

5 August 2017

Voest EE

series ordinal

1 reference

5 August 2017

publication date

1 November 2002

1 reference

Molecular and Cellular Endocrinology

5 August 2017

published in

1 reference

5 August 2017

volume

197

1 reference

5 August 2017

issue

1-2

1 reference

5 August 2017

page(s)

239-250

1 reference

Tissue factor expression and angiogenesis in human prostate carcinoma

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Advances in angiogenesis research: relevance to urological oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Expression of vascular endothelial growth factor receptors in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

The implications of angiogenesis for the biology and therapy of cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Induction of angiogenesis during the transition from hyperplasia to neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Antiangiogenic activity of prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Suramin treatment in hormone- and chemotherapy-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Angiogenesis: the role of the microenvironment in flipping the switch.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

New therapeutic concepts in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Future prospects in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Biological consequences of tumor hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

International trends and patterns of prostate cancer incidence and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Angiogenesis in urological malignancy: prognostic indicator and therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

The role of cyclooxygenase-2 in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Clinical trials of immunotherapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Effect of Suramin on Human Prostate Cancer Cells in Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Transforming growth factor-beta in benign and malignant prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Redefining the target: chemotherapeutics as antiangiogenics

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Abnormal level of retinoic acid in prostate cancer tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Marimastat (BB2516): current status of development

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Differential antiproliferative activities of alpha- and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Impotence following radical prostatectomy: insight into etiology and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Angiogenic peptides in prostatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Expression of cyclooxygenase-2 in prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900262-9

7 January 2021

10.1016/S0303-7207(02)00262-9

Identifiers

DOI

1 reference

5 August 2017

1 reference